Paliperidone Viatris (Paliperidone)

Paliperidone is an atypical antipsychotic that modulates dopamine and serotonin pathways in psychotic disorders.

• Schizophrenia: Reduces the frequency and severity of psychotic episodes and improves overall functioning.
• Schizoaffective disorder: Alleviates both mood and psychotic symptoms, supporting long‑term stability.
• Maintenance therapy: Helps prevent relapse in patients with a history of recurrent psychotic episodes.

• Paliperidone acts as a potent antagonist at dopamine D2 and serotonin 5‑HT2A receptors, with additional moderate affinity for α1‑adrenergic, histamine H1 and muscarinic receptors. By blocking D2 receptors in mesolimbic pathways, it reduces positive psychotic symptoms, while 5‑HT2A antagonism mitigates negative and cognitive symptoms, contributing to overall antipsychotic efficacy.

Paliperidone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Akathisia: Restlessness and an urge to move constantly.
• Weight gain: Increased appetite leading to modest weight increase.
• Somnolence: Drowsiness or feeling unusually sleepy.
• Dry mouth: Reduced salivation causing a dry sensation in the mouth.
• Constipation: Decreased bowel motility resulting in infrequent stools.
• Elevated prolactin: Hormonal changes that may cause menstrual irregularities or galactorrhea.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever, muscle rigidity and autonomic instability.
• Tardive dyskinesia: Persistent involuntary movements, often of the face and tongue.
• Seizures: Increased risk of convulsive episodes, particularly at higher doses.
• Orthostatic hypotension: Marked drop in blood pressure upon standing, causing dizziness or fainting.
• Cardiac arrhythmias: QT‑interval prolongation that may predispose to serious rhythm disturbances.

When prescribing Paliperidone, clinicians should consider several safety aspects.

• Cardiovascular assessment: Evaluate baseline ECG and monitor for QT prolongation.
• Metabolic monitoring: Track weight, glucose and lipid profiles regularly.
• Prolactin levels: Check for hyperprolactinemia if menstrual changes or galactorrhea occur.
• Elderly patients: Use lower initial doses and monitor for falls and sedation.
• Pregnancy and lactation: Weigh potential benefits against risks; avoid unless clearly needed.
• Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Paliperidone can interact with several medication classes, requiring careful management. Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors: May increase paliperidone plasma concentrations and heighten adverse‑event risk.

• QT‑prolonging drugs: Combined effect can raise the likelihood of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CNS depressants: May enhance sedation and impair psychomotor performance.
• Antihypertensive agents: Potential additive effect on blood pressure lowering.
• Drugs affecting renal excretion: Altered clearance may require dose adjustment.